OHSU Knight Cancer Institute: Leukemia trials
The registry lists 22 Leukemia studies with OHSU Knight Cancer Institute as lead sponsor. 0 are open to participants now and 13 have results posted.
Phase 1 5Phase 2 14Phase 3 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03557970Phase 2Results posted
- Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid LeukemiaCompletedNCT02092324Phase 2Results posted
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
- Dasatinib in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT01441882Phase 2Results posted
- Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaTerminatedNCT01005914Phase 2Results posted
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
- Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00428077Phase 2Results posted
- Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CMLTerminatedNCT00416884Phase 2Results posted
- Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
- Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00253513Phase 1/2Results posted
- Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
- Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00022490Phase 2Results posted
- Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00015847Phase 2Results posted
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- Compassionate Use PonatinibNo longer availableNCT01549548
- MRI Assessment of Leukemia Response to TherapyCompletedNCT01537159
- Blood Samples From Patients on a Clinical Trial to CINV During HSCTTerminatedNCT00900068
- Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy VolunteersCompletedNCT00899795
- Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
- G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic DisordersTerminatedNCT00253552Not applicable
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00053248Phase 1/2